HCV entry receptors as potential targets for siRNA-based inhibition of HCV

Genetic Vaccines and Therapy

Volumn 9, Issue , 2011, Pages

  Jahan, Shah ^a   Samreen, Baila ^a   Khaliq, Saba ^a   Ijaz, Bushra ^a   Khan, Mahwish ^a   Siddique, Muhammad H ^a   Ahmad, Waqar ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CELL SURFACE RECEPTOR; CLAUDIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; TETRASPANIN; VIRUS RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

HEPATITIS C VIRUS;

EID: 80052605116     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-9-15     Document Type: Article

References (85)

1. Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003, 10(Suppl 1):S27-S38.
2. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008, 41:4-8.
3. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007, 4:622-634. 10.1038/ncpgasthep0961, 17978819.
4. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004, 24(Suppl 2):3-8.
5. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, et al. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009, 15:5080-5085. 10.3748/wjg.15.5080, 2768888, 19860002.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
7. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008, 3:e2660. 10.1371/journal.pone.0002660, 2442186, 18628977.
8. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, et al. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006, 12:4836-4842.
9. Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007, 170:478-489. 10.2353/ajpath.2007.060789, 1851861, 17255316.
10. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82:569-574. 10.1128/JVI.01443-07, 2224376, 17942559.
11. Zekri AR, Bahnassy AA, El-Din HM, Salama HM. Consensus siRNA for inhibition of HCV genotype-4 replication. Virol J 2009, 6:13. 10.1186/1743-422X-6-13, 2661880, 19173711.
12. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Pervaiz A, et al. Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virol J 2010, 7:318. 10.1186/1743-422X-7-318, 2992066, 21073745.
13. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
14. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197:633-642. 10.1084/jem.20021756, 2193821, 12615904.
15. Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 2003, 546:385-390. 10.1016/S0014-5793(03)00635-5, 12832074.
16. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005, 79:8400-8409. 10.1128/JVI.79.13.8400-8409.2005, 1143753, 15956584.
17. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007, 81:8101-8111. 10.1128/JVI.00127-07, 1951279, 17522218.
18. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008, 65:100-112. 10.1007/s00018-007-7291-8, 17914604.
19. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004, 85:1497-1507. 10.1099/vir.0.79967-0, 1810391, 15166434.
20. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005, 79:8400-8409. 10.1128/JVI.79.13.8400-8409.2005, 1143753, 15956584.
21. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007, 81:8101-8111. 10.1128/JVI.00127-07, 1951279, 17522218.
22. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008, 65:100-112. 10.1007/s00018-007-7291-8, 17914604.
23. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999, 73:6235-6244. 112700, 10400713.
24. Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008, 65:100-112. 10.1007/s00018-007-7291-8, 17914604.
25. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
26. Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 2003, 77:10677-10683. 10.1128/JVI.77.19.10677-10683.2003, 228455, 12970454.
27. Meola A, Sbardellati A, Bruni EB, Cerretani M, Pezzanera M, Ceccacci A, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 2000, 74:5933-5938. 10.1128/JVI.74.13.5933-5938.2000, 112089, 10846074.
28. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
29. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999, 57:223-229. 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4, 10022791.
30. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-5025. 10.1093/emboj/cdf529, 129051, 12356718.
31. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007, 46:1722-1731. 10.1002/hep.21994, 18000990.
32. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 2004, 101:7270-7274. 10.1073/pnas.0402253101, 409908, 15123813.
33. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41:265-274. 10.1002/hep.20542, 15660396.
34. Wunschmann S, Muller HM, Stipp CS, Hemler ME, Stapleton JT. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J Infect Dis 2006, 194:1058-1067. 10.1086/507647, 16991080.
35. Evans MJ, Von HT, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805. 10.1038/nature05654, 17325668.
36. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886. 10.1038/nature07684, 2762424, 19182773.
37. Hannon GJ. RNA interference. Nature 2002, 418:244-251. 10.1038/418244a, 12110901.
38. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, et al. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 2010, 28:27-34. 10.1016/j.biotechadv.2009.08.004, 19729057.
39. Sharp PA. RNA interference--2001. Genes Dev 2001, 15:485-490. 10.1101/gad.880001, 11238371.
40. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
41. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
42. Jahan S, Khaliq S, Ijaz B, Ahmad W, Hassan S. Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J 2011, 8:155. 10.1186/1743-422X-8-155, 3080829, 21457561.
43. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, et al. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006, 12:4836-4842.
44. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
45. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
46. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
47. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
48. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, et al. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006, 12:4836-4842.
49. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
50. Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, et al. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol 2007, 170:478-489. 10.2353/ajpath.2007.060789, 1851861, 17255316.
51. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82:569-574. 10.1128/JVI.01443-07, 2224376, 17942559.
52. Seo MY, Abrignani S, Houghton M, Han JH. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 2003, 77:810-812. 10.1128/JVI.77.1.810-812.2003, 140638, 12477890.
53. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003, 4:602-608. 10.1038/sj.embor.embor840, 1319196, 12740604.
54. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003, 100:2014-2018. 10.1073/pnas.252783999, 149950, 12566571.
55. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82:569-574. 10.1128/JVI.01443-07, 2224376, 17942559.
56. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005, 41:265-274. 10.1002/hep.20542, 15660396.
57. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005, 79:8217-8229. 10.1128/JVI.79.13.8217-8229.2005, 1143705, 15956567.
58. Evans MJ, Von HT, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805. 10.1038/nature05654, 17325668.
59. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009, 83:2011-2014. 10.1128/JVI.01888-08, 2643775, 19052094.
60. Timpe JM, McKeating JA. Hepatitis C virus entry: possible targets for therapy. Gut 2008, 57:1728-1737. 10.1136/gut.2007.141630, 19022929.
61. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007, 46:1722-1731. 10.1002/hep.21994, 18000990.
62. Evans MJ, Von HT, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805. 10.1038/nature05654, 17325668.
63. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007, 81:8101-8111. 10.1128/JVI.00127-07, 1951279, 17522218.
64. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
65. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-5025. 10.1093/emboj/cdf529, 129051, 12356718.
66. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999, 57:223-229. 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4, 10022791.
67. Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006, 87:2983-2991. 10.1099/vir.0.82033-0, 2043115, 16963757.
68. Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006, 80:11074-11081. 10.1128/JVI.01150-06, 1642172, 16956946.
69. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992, 181:293-300. 10.1007/BF00198849, 1335546.
70. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999, 96:12766-12771. 10.1073/pnas.96.22.12766, 23090, 10535997.
71. Krieger M. Charting the fate of the good cholesterol: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999, 68:523-558. 10.1146/annurev.biochem.68.1.523, 10872459.
72. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626. 10.1126/science.1114016, 15947137.
73. Takyar ST, Li D, Wang Y, Trowbridge R, Gowans EJ. Specific detection of minus-strand hepatitis C virus RNA by reverse-transcription polymerase chain reaction on PolyA(+)-purified RNA. Hepatology 2000, 32:382-387. 10.1053/jhep.2000.9094, 10915746.
74. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197:633-642. 10.1084/jem.20021756, 2193821, 12615904.
75. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003, 278:41624-41630. 10.1074/jbc.M305289200, 12913001.
76. Voisset C, Callens N, Blanchard E, Op De BA, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005, 280:7793-7799.
77. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82:569-574. 10.1128/JVI.01443-07, 2224376, 17942559.
78. Jahan S, Khaliq S, Ijaz B, Ahmad W, Hassan S. Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J 2011, 8:155. 10.1186/1743-422X-8-155, 3080829, 21457561.
79. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
80. Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol 2008, 82:569-574. 10.1128/JVI.01443-07, 2224376, 17942559.
81. Evans MJ, Von HT, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805. 10.1038/nature05654, 17325668.
82. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004, 78:1448-1455. 10.1128/JVI.78.3.1448-1455.2004, 321402, 14722300.
83. Khaliq S, Jahan S, Ijaz B, Ahmad W, Asad S, Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol 2011, 156:433-442. 10.1007/s00705-010-0887-6, 21161551.
84. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, et al. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 2010, 28:27-34. 10.1016/j.biotechadv.2009.08.004, 19729057.
85. Henry SD, van der WP, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006, 14:485-493. 10.1016/j.ymthe.2006.04.012, 16872906.